Go Deep
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,086 | -0.6 | 1.06 | 0.00 | 121.24 |
| Oct 2026 | 21,040 | -0.6 | 1.08 | 0.00 | 123.13 |
| Oct 2026 | 19,172 | -0.6 | 1.11 | 0.00 | 126.11 |
| Oct 2026 | 19,240 | -0.6 | 1.08 | 0.00 | 123.26 |
| Oct 2026 | 19,354 | -0.5 | 1.04 | 0.00 | 118.23 |
| Oct 2026 | 19,651 | -0.5 | 0.93 | 0.00 | 105.72 |
Alzamend Neuro, Inc. Quarterly Results
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -3,027,002.0 | -2,869,949.0 | -2,198,991.0 | -1,000,758.0 |
| EPS | -0.7 | — | -0.6 | -0.3 |
Alzamend Neuro, Inc. Revenue & Profit: Last 5 Years
| Line Item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -8,772,382.0 | -4,514,853.0 | -9,947,746.0 | -14,878,167.0 | — |
| EPS | -2.6 | -11.3 | -132.3 | -228.9 | — |
Alzamend Neuro, Inc. Balance Sheet
| Line Item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,079,363.0 | 4,602,983.0 | 631,588.0 | 5,915,625.0 | — |
| Total Liabilities | 1,346,152.0 | 634,761.0 | 3,225,773.0 | 2,870,122.0 | — |
| Total Equity | 733,211.0 | 3,968,222.0 | -2,594,185.0 | 3,045,503.0 | — |
Owes vs Owns
Alzamend Neuro, Inc. owed $0.32 for every $1 it owned in Jul 2026, down from $0.49 in Apr 2023.
| Period | Jul 2026 | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.32× | 0.65× | 0.14× | 5.11× | 0.49× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Alzamend Neuro, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Apr 2026
Cash & short-term investments 34.2%Fixed assets (tangible) 15.1%Other assets 50.7%
How it's funded — Apr 2026
Payables 64.7%Shareholders' equity 35.3%
| Line Item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 0.7 | 3.9 | 0.4 | 5.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.3 | 0.4 | 0.2 | 0.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.1 | 0.2 | 0.1 | 0.7 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.3 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 1.3 | 0.6 | 2.9 | 2.9 |
| Other liabilities | 0.0 | 0.0 | 0.0 | 0.0 |
| Shareholders' equity | 0.7 | 4.0 | -2.6 | 3.0 |
| Net tangible assets | 0.7 | 4.0 | -2.6 | 3.0 |
Alzamend Neuro, Inc. Cash Flow
| Line Item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
| Operating Activities | -8,067,813.0 | -6,568,186.0 | -8,269,993.0 | -8,923,152.0 | — |
| Investing Activities | 0.0 | -300,000.0 | -147,243.0 | 0.0 | — |
| Financing Activities | 4,829,844.0 | 10,440,796.0 | 3,652,425.0 | 200.0 | — |